Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.
V. Camus
(1)
,
R. Houot
(2)
,
G. Brisou
(3)
,
B. Tessoulin
(4)
,
S. Bailly
(5)
,
P. Sesques
(6)
,
J. Decroocq
(7)
,
D. Krzisch
(8)
,
L. Obéric
(9)
,
F. Lemonnier
(10)
,
K. Bouabdallah
(11)
,
A. Campidelli
(12)
,
L. Tounes
(13)
,
J. Abraham
(14)
,
C. Herbaux
(15)
,
Franck Morschhauser
(16)
,
G. Damaj
(17)
,
S. Guidez
(18)
,
S. Carras
(19)
,
L. M. Fornecker
(20)
,
S. Choquet
(21)
,
O. Hermine
(22)
,
J. Paillassa
(23)
,
A. Chauchet
(24)
,
O. Casasnovas
(25)
,
L. Drieu La Rochelle
(26)
,
C. Castilla-Llorente
(27)
,
M. Joris
(28)
,
V. Dupont
(29)
,
A. Marquet
(29)
,
S. Le Gouill
(30)
,
F. Jardin
(1)
1
CLCC Henri Becquerel -
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
2 Centre Hospitalier Universitaire [Rennes]
3 IPC - Institut Paoli-Calmettes
4 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
5 Université de Clermont-Ferrand
6 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
7 IC UM3 (UMR 8104 / U1016) - Institut Cochin
8 AP-HP - Hopital Saint-Louis [AP-HP]
9 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
10 Hôpital Henri Mondor
11 CHU Bordeaux
12 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
13 Inserm U354/Hôpital Saint-Antoine-APHP - Immunochimie des Régulations Cellulaires et des Interactions Virales
14 Service d'Hématologie biologique [CHU Limoges]
15 CHU Montpellier
16 GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365
17 UNICAEN - Université de Caen Normandie
18 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
19 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
20 ICANS - Institut de Cancérologie de Strasbourg Europe
21 CHU Pitié-Salpêtrière [AP-HP]
22 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
23 CHU Angers - Centre Hospitalier Universitaire d'Angers
24 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
25 CHU Dijon
26 CHU Trousseau [Tours]
27 Département d'hématologie [Gustave Roussy]
28 CHU Amiens-Picardie
29 LYSARC - The Lymphoma Academic Research Organisation [Lyon]
30 ICSC - Institut Curie - Saint Cloud
2 Centre Hospitalier Universitaire [Rennes]
3 IPC - Institut Paoli-Calmettes
4 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
5 Université de Clermont-Ferrand
6 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
7 IC UM3 (UMR 8104 / U1016) - Institut Cochin
8 AP-HP - Hopital Saint-Louis [AP-HP]
9 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
10 Hôpital Henri Mondor
11 CHU Bordeaux
12 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
13 Inserm U354/Hôpital Saint-Antoine-APHP - Immunochimie des Régulations Cellulaires et des Interactions Virales
14 Service d'Hématologie biologique [CHU Limoges]
15 CHU Montpellier
16 GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365
17 UNICAEN - Université de Caen Normandie
18 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
19 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
20 ICANS - Institut de Cancérologie de Strasbourg Europe
21 CHU Pitié-Salpêtrière [AP-HP]
22 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
23 CHU Angers - Centre Hospitalier Universitaire d'Angers
24 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
25 CHU Dijon
26 CHU Trousseau [Tours]
27 Département d'hématologie [Gustave Roussy]
28 CHU Amiens-Picardie
29 LYSARC - The Lymphoma Academic Research Organisation [Lyon]
30 ICSC - Institut Curie - Saint Cloud
Résumé
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 CAR T-cell is currently debated. We analyzed large B-cell lymphoma patients in the DESCAR-T registry treated with axi-cel or tisa-cel in ≥3rd line (L3+) and TAFA-LEN before (n=15, 'TL-pre-CAR-T' set) or directly after (n=52, 'TL-post-CAR-T' set) CAR T-cell. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR-T set. In the TL-post-CAR-T' set, the median follow-up duration (mFUD) was 7 months, and the median progression-free survival, overall survival and duration of response since the 1st treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7 and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell (mPFS2: 5.6 vs. 2 months, p=0.0138; mOS2: not reached vs. 3.8 months, p=0.0034). bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs. 24.9% and 11.6% vs. 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 [2-2.6] vs. 2.4 [1.5-4.2] months, p=0.91; mOS2: 3.3 [1.8-6.4] vs. 5.5 [4.4-6.3] months, p=0.06). In an exploratory analysis of the TL-pre-CAR-T set (mFUD since CAR T-cell: 2.8 months), the median TAFA-LEN treatment duration prior to CAR-T was 3.7 months and no patients were reported to become CD19 negative. The bORR, bCRR, 6-month PFS and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1% and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatments improved outcomes of patients who relapsed after CAR T-cell.